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The mechanisms by which viruses evade or suppress the immune response and 
persist in the host is one of the most intriguing problems in virology. A  variety 
of viruses, such as herpes simplex, cytomegalovirus, Epstein-Barr virus, rubella, 
measles, hepatitis B, etc., are known to cause persistent infections in humans (1). 
Persistent viral infections are medically significant due to their association with 
a variety of diseases (1). In recent years, it has become evident that a number of 
chronic human diseases such as subacute sclerosing panencephalitis, progressive 
multifocal  leukoencephalopathy,  and  progressive  rubella  panencephalitis  are 
caused by persistent viral infections (2,  3).  A  viral etiology is also suspected in 
several  other  chronic  human  illnesses  (2,  3).  In  addition,  the  persistence  of 
hepatitis B virus in an estimated 200 million persons constitutes a  major public 
health problem of worldwide concern (4). Thus, there is a  need to understand 
the  host  and  viral  factors  involved  in  the  establishment  and  maintenance  of 
persistent infections. 
Persistent  infection  of the  mouse  with  lymphocytic  choriomeningitis  virus 
(LCMV) 1 is an excellent experimental model for studying the interaction between 
the virus and the host's immune system, and in defining the conditions that lead 
to  viral  clearance  or  persistence  (5,  6).  LCMV  is  maintained  in  nature  as  a 
persistent infection (carrier state) in  mice, as evident in  many wild mice of the 
Mus musculus strain. The life-long carrier state is readily established in laboratory 
mice by injecting them at birth with  LCMV.  Such carrier mice make antibody 
responses against  the  virus,  but  contain  minimal  amounts  of or no  detectable 
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LCMV-specific  cytotoxic  T  lymphocytes  (CTL)  (6-10).  This  classic  model  of 
viral  persistence  has  been  extensively studied  during  the  past  50  years,  but  a 
major unresolved  question  is  the  mechanism  of suppression  of CTL  responses 
and its role in persistence (5, 6,  11). 
In this paper, we describe our studies on the mechanism of LCMV persistence 
and suppression of CTL responses in BALB/c WEHI mice infected with LCMV 
Armstrong strain. We found that spleen cells from carrier mice actively suppress 
the  expected  LCMV-specific  CTL  response of spleen  cells  from  normal  adult 
mice,  and  that  this  suppression  is  due  to  the  presence  of genetic  variants  of 
LCMV  in  spleens  of  carrier  mice.  We  propose  that  these  LCMV  variants, 
generated during infection in vivo, play a  crucial role in the maintenance of the 
carrier state in mice. 
Materials and  Methods 
Mice.  BALB/c WEHI (H-2  d) mice were obtained from the breeding colony at Scripps 
Clinic and Research Foundation. 
Virus.  The origin of the LCMV Armstrong CA 1371  strain used in this study has been 
described (12). The virus was triple plaque-purified on Vero cells and grown in BHK-21 
cells. Virus stocks at the passage 1 or passage 2 level were used in all experiments. LCMV 
clones 1, 3,  13, and 14 were isolated from the spleens of 2-mo-old BALB/c WEHI carrier 
mice infected at birth with LCMV Armstrong CA 1371. Spleens from three carrier mice 
were pooled,  homogenized,  and  centrifuged  at  1,200  rpm  for  10  min  to  remove the 
cellular  debris.  The  clarified  homogenate  was  titrated  on  Vero  cell  monolayers and 
isolated plaques were picked from the plates. These clones were subjected to two additional 
cycles of plaque to plaque purification and then grown in BHK-21 cells.  All four spleen 
isolates, clones  1, 3,  13, and  14, were authenticated as LCMV by their positive reactivity 
with  monoclonal antibodies  specific for the  nucleoprotein  and  glycoprotein of LCMV 
Armstrong (13).  Vaccinia virus (IHD-J strain)  used in  this study was a  gift of Dr. Sam 
Dales, University of Western Ontario, London, Ontario, Canada. 
Adoptive  Transfer Experiments.  6-10-wk-old normal  or carrier BALB/c WEHI mice 
were  used as  donors  of spleen  cells.  After sacrifice,  their  spleens were  harvested and 
single-cell suspensions were prepared in  RPMI  1640  medium supplemented with  10% 
heat-inactivated fetal calf serum, antibiotics, and L-glutamine (complete RPMI). Erythro- 
cytes were removed by treatment with  0.83%  NH4C1 solution.  One pool was made of 
spleen cells  from normal mice and another of spleen cells from carrier mice.  5  x  107 
viable  spleen  cells  were  transferred  intravenously  into  2-4-mo-old  normal  or  carrier 
BALB/c WEHI mice irradiated (600  rad)  1 d  previously. Mice reconstituted with both 
carrier and normal spleen cells received 5 x  107 cells from carrier mice and 5 x  10 ~ cells 
from  normal  mice.  At  the  time  of the  cell  transfer  all  recipient  mice  were  infected 
intravenously with the indicated dose and strain of LCMV. In some experiments mixtures 
of spleen and lymph node cells (ratio, 3:1) were used to reconstitute the irradiated mice. 
Cytotoxicity Assay.  Single-cell suspensions of spleens,  free of erythrocytes, were  pre- 
pared in complete RPMI medium and tested for cytotoxicity on uninfected and LCMV- 
infected BALB CI-7 (H-2  d) fibroblasts. BALB C1-7 cells were infected with the indicated 
LCMV strain at a multiplicity of infection (MOI) of 0.5 plaque-forming units (PFU) per 
cell and used  18-24 h later for the assay. The target cells were labeled with ~lCr and the 
cytotoxicity assay was performed as previously described (14,  15). The test duration was 
6-8 h. The percent specific 51Cr release was calculated by the formula: [(Sample release 
-  spontaneous release [cpm])/(maximum release -  spontaneous release [cpm])] x  I00. 
Vaccinia virus CTL assays were done in  the same manner except that  B.10.D2  (H-2  d) 
fibroblasts were used as targets. The B. 10.D2 cells were infected with vaccinia virus (IHD- 
J  strain) at an  MOI of 10  PFU/cell  and  used  2 h  later for the 5~Cr-release  assay. Test 
duration was 6 h. All samples were assayed in triplicate and standard error was <2%. AHMED  ET  AL.  523 
Virus  Titrations.  Infectious  LCMV  was  quantitated  by  plaque  assay  on  Vero  cell 
monolayers. 7.5  X  10 ~ Vero cells were plated in  35-mm wells  in  6-well  dishes (Costar, 
Cambridge, MA). The plates were incubated at 37°C and used the following day for the 
assay  when  the  cell  monolayers were  confluent.  The  medium  was  removed  and  the 
samples to be titrated were added to the cells (0.2 ml vol). After adsorption for 60 min at 
37°C,  the cells were overlaid with  3  ml of 0.5%  Seakem agarose (FMC Corporation, 
Rockland,  ME)  in  Medium  199  (Gibco Laboratories, Grand  Island, NY) supplemented 
with 5% heat-inactivated fetal calf serum, antibiotics, and L-glutamine. The plates were 
incubated for 5 d at 37°C and then overlaid with 2.0 ml of 0.5% agarose in Medium 199 
containing 0.01%  neutral  red  (Gibco Laboratories).  Plaques were scored the following 
day. 
Antibody Titrations.  LCMV-specific antibody was measured by a solid phase enzyme- 
linked immunosorbent assay (ELISA) using purified virus as the antigen.  LCMV Arm- 
strong  strain  was  grown  in  BHK-21  cells  and  purified  on  Renografin  gradients  as 
previously described  (12).  The purified  virus was diluted  in  phosphate-buffered saline 
(PBS),  sonicated  to disrupt  clumps, and  the  protein  concentration  was determined  by 
Lowry's method  (16)  using  bovine  serum  albumin  as  the  standard.  Microtiter  plates 
(Linbro Titertek; Flow Laboratories, McLean, VA) were coated with 200 ng/well of viral 
antigen  in  a  0.1  ml vol. After overnight incubation at room temperature,  free binding 
sites of the polystyrene wells were blocked with 0.15 ml/well of PBS supplemented with 
10%  (vol/vol) heat-inactivated fetal calf serum,  0.2%  (vol/vol) Tween 20,  and 0.5  mM 
merthiolate. After  1 h  or more incubation  at room temperature, antigen-coated plates 
were used for antibody-binding assays. Viral antigen-coated plates prepared in this manner 
showed a high level of binding to LCMV-specific monoclonal antibodies directed against 
the LCMV nucleocapsid protein and the two glycoproteins, GP-1 and GP-2 (13). Thus, 
this method allows us to measure antibodies directed against the three major structural 
proteins of LCMV.  To measure  LCMV-specific antibody  in  the  serum samples, serial 
threefold dilutions of the samples were incubated in antigen-coated plates for 75-90 rain 
at room temperature. The plates were washed three times with PBS containing 0.05% 
(vol/vol) Tween 20,  and horseradish  peroxidase-labeled, affinity-purified antibodies to 
mouse IgG and IgM (Boehringer Mannheim Biochemicals, Indianapolis, IN) were added. 
After 75-90 min incubation, the plates were washed as above and 0.1  ml of the substrate 
solution, consisting of 3 mM hydrogen peroxide and 2.2 mM 0-phenylenediamine in 0.1 
M  sodium  citrate  buffer, pH  5.0,  was added  to  each  well.  The enzyme reaction  was 
terminated after 30 min by adding 0.1  ml of 1 N  HCI into each well.  Optical densities 
were read (OD492) with a Titertek Multiskan photometer (Eflab, Helsinki, Finland). In all 
experiments, plates coated with purified measles virus (Edmonston strain) (200 ng/well) 
were included as controls. The LCMV-specific antibody titer was determined by subtract- 
ing the binding (0D492) to measles virus-coated plates from the binding (OD492)  to LCMV- 
coated plates.  The  LCMV-specific antibody titer  is expressed as  the  reciprocal of the 
highest dilution showing an OD492 reading >2 standard deviations from the OD49z reading 
of serum samples from mock-infected mice (average of at least six control mice). 
Results 
LCMV-specific CTL and Antibody Responses During Acute and Persistent LCMV 
Infection.  Infection  of adult  BALB/c  WEHI  mice with  LCMV  Armstrong  in- 
duced a vigorous cellular and humoral response against the virus. Table I shows 
the LCMV-specific CTL and antibody response of six adult mice infected with 2 
x  105  PFU i.v. of LCMV Armstrong 8 d  previously. All six mice bad high levels 
of CTL and antibody.  Such acutely infected mice cleared the virus within  8-10 
d  postinfection  (data  not  shown).  When  BALB/c  WEHI  mice are  infected  at 
birth  with  LCMV  Armstrong (by any route  of injection),  they become carriers 
with  life-long viremia and  contain  high  levels of infectious  LCMV  in all  major 
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TABLE  1 
LCMV-spec~c CTL and Antibody Responses in Acutely and Persistently Infected BALB/c 
WEHI Mice 
Mouse  Status of mice  No. 
CTL response* 
Percent specific 5JCr release from 
BALB CI-7 (H-2  d) targets 
LCMV Armstrong 
Uninfected  infected 
E/T ratio  E/T ratio 
5:1  25:1  50:1  5:1  25:1  50:1 
Antibody 
response* 
LCMV-spe- 
cific anti- 
body ELISA 
titer (log 2) 
Mock infected  ~ 
Acutely infected  I 
1  0  0  3  0  0  1  <4.7 
2  0  1  8  1  3  3  <4.7 
3  2  4  3  3  5  6  <4.7 
4  3  2  5  0  4  7  <4.7 
5  0  5  6  2  4  9  <4.7 
6  0  5  9  3  3  7  <4.7 
1  1  3  5  22  37  79  15.3 
2  1  1  3  12  39  63  15.9 
3  2  1  5  34  67  76  15.9 
4  0  2  1  28  45  72  15.8 
5  0  4  4  21  44  78  15.7 
6  2  3  7  19  51  62  16.3 
Persistently infected ! (car-  1  0  0  0  0  0  2  12.0 
rier mice)  2  0  4  5  2  2  6  <4.7 
3  2  3  3  2  2  4  <4.7 
4  4  2  3  4  5  7  <4.7 
5  5  2  4  2  2  5  9.8 
6  0  1  5  0  1  3  7.5 
* CTL activity in  the  spleen  was  determined  by a  5~Cr release assay.  Test  duration  was  6-8  h. 
Spontaneous release was <20%. All samples were assayed in triplicate and standard error was <2%. 
E/T, effector/target. 
LCMV-specific antibody in serum was determined by an EL1SA using purified virus as antigen. 
8-wk-old mice injected intravenously with 0.2 ml of medium.  LCMV-specific CTL and antibody 
were checked 7 d later. 
8-wk-old mice injected intravenously with 2 x  105 PFU of LCMV Armstrong. LCMV-specific CTL 
and antibody were checked 7 d postinfection. 
I Mice injected intracerebrally with  104  PFU of LCMV  Armstrong at birth  (<24  h  old).  LCMV- 
specific CTL and antibody were checked when mice were 8-wk-old. 
nodes  of  1-3-mo-old  carrier  mice  in  many  different  experiments  and  have  not 
detected  any  CTL  activity. The  level of killing exhibited  by spleen cells from  six 
2-mo-old  carrier  mice  on  LCMV-infected  and  uninfected  syngeneic  targets  is 
shown  in  Table  I.  The  killing is  minimal  and  not  significantly  higher  than  that 
by  spleen  cells  from  mock-infected  BALB/c  WEHI  mice  (Table  I).  In  contrast 
to  the absence  of detectable  CTL  activity,  LCMV-specific  antibody  was  present 
in  the  sera  of  BALB/c  WEHI  carrier  mice.  However,  the  amount  of antibody 
was  low  and  detectable  in  only  three  out  of  six  mice  (Table  I).  It  should  be AHMED ET  AL.  525 
pointed out that the ELISA test we used measures free antibody and that LCMV- 
specific antibody present  in  immune complexes in carrier  mice is not detected 
by this method. 
Effect of  Normal and Carrier Environment on the Generation of  LCMV-specific CTL 
and Antibody Responses.  To further  investigate the  mechanism  of low respon- 
siveness of BALB/c WEHI  carrier  mice  to  LCMV,  we adoptively transferred 
spleen cells from carriers into irradiated  normal  recipients (C ---* N) and spleen 
cells  from  normal  adult  mice  into  irradiated  carrier  recipients  (N  ~  C).  All 
recipient mice were injected intravenously with  LCMV Armstrong at the time 
of cell transfer, and  LCMV-specific antibody and CTL responses were checked 
8  d  postinfection.  As  the  results  in  Table  II  show,  normal  irradiated  mice 
reconstituted  with  normal  spleen  cells  (N  --~  N)  made  potent  LCMV-specific 
CTL and antibody responses. In contrast, C ~  N mice made no detectable CTL 
response and a low antibody response. Since the irradiated normal recipient mice 
provide  a  source  of antigen-presenting  cells,  this  result  shows  that  the  low 
responsiveness of carrier spleen cells to ECMV is not simply due to a  defect in 
antigen-presenting  cells. When normal spleen cells were transferred into irradi- 
ated carrier recipients (N ~  C), there was no detectable CTL activity. This was 
in striking contrast to the high  CTL activity seen in N  ~  N  mice. However, N 
C  mice made an  LCMV-specific antibody response about equivalent to N 
N mice. These results show that the carrier environment suppressed the LCMV- 
specific CTL response of spleen cells from normal adult mice but had negligible 
effect on LCMV-specific antibody response. 
Spleen  cells  from  LCMV  carrier  mice  do  not  have  a  generalized  defect  in 
generating  antiviral  CTL  responses, as shown  in  Table III.  The  magnitude  of 
the vaccinia-specific CTL response  upon challenge  with vaccinia virus is about 
equal in N ~  N and C ~  N mice. 
Spleen Cells from Carrier Mice Actively Suppress LCMV-spec~c  CTL Response of 
Spleen Cells from Normal Adult Mice But Have No Effect on LCMV-specific Antibody 
Response.  Because the carrier environment actively suppressed LCMV-specific 
CTL responses (Table II), we next examined whether carrier spleen cells could 
transfer the suppression.  Irradiated  normal  mice were reconstituted with either 
(a) 5  X  10 7 spleen cells from normal mice (N ~  N), (b) 5 X  10 7 spleen cells from 
carrier mice (C ~  N), or (c) equal mixtures (5 X  10 7 +  5 ×  10 7) of spleen cells 
from carrier and normal mice (C +  N ~  N). One group of irradiated  mice was 
not given spleen cells (None ~  N). In some experiments, mixtures of spleen and 
lymph node cells (ratio,  3:1) were used to reconstitute the irradiated  mice. The 
results of these experiments were identical to those using spleen cells alone. All 
irradiated recipient mice were challenged with LCMV Armstrong at the time of 
the cell transfer,  and,  1,  3, 6,  8,  10, and  15 d  later,  were checked for LCMV- 
specific CTL, LCMV-specific antibody, and infectious LCMV in spleens (Fig.  1). 
As expected, None ~  N mice did not generate any detectable immune response 
against LCMV and contained high  levels of virus in their spleens. N --~ N  mice 
made strong LCMV-specific CTL and antibody responses and cleared the virus 
infection by day 10. Their CTL and antibody responses peaked at day 8, but the 
CTL activity disappeared by day  15, while antibody remained at high  levels. C 
N  mice  made  no  detectable  CTL  response,  a  minimal  antibody  response 526  VIRAL  PERSISTENCE:  VIRUS  VARIANTS  AND  CTL  RESPONSE 
TABLE  I1 
Inability of Spleen Cells  from Carrier Mice to Generate LCMV-specific CTL Responses in 
Normal Recipients, and Suppression of CTL Response of Spleen Cells  from Normal Adult Mice 
in Carrier Recipients 
LCMV-specific CTL in spleen (8 d post- 
infection) 
Percent specific 51Cr release from BALB 
CI-7 (H-2  d) targets* 
Source of spleen  Recipient (600  LCMV-spe- 
cells  LCMV Armstrong 
transferred*  rad)  Uninfected  infected  cific antibody 
in serum (8 d 
E/T ratio  E/T ratio  postinfection) 
25:1  50:1  25:1  50:1  ELISA titer 
(log 2) 
None  Normal  0  NT  ~  1  NT  <4.7 
None  Normal  0  NT  0  NT  <4.7 
None  Normal  0  NT  0  NT  <4.7 
None  Normal  0  NT  0  NT  <4.7 
Normal  Normal  3  1  57  64  15.8 
Normal  Normal  0  2  58  62  15.1 
Normal  Normal  0  3  49  54  15.3 
Normal  Normal  4  3  38  59  14.6 
Carrier  Normal  2  0  1  0  4.7 
Carrier  Normal  0  0  2  0  <4.7 
Carrier  Normal  3  0  1  2  5.6 
Carrier  Normal  0  0  0  1  <4.7 
None  Carrier  0  NT  0  NT  <4.7 
None  Carrier  2  NT  0  NT  6.8 
None  Carrier  0  NT  2  NT  <4.7 
None  Carrier  1  NT  1  NT  7.1 
Normal  Carrier  0  5  1  0  14.3 
Normal  Carrier  0  0  1  3  14.5 
Normal  Carrier  3  2  0  1  14.9 
Normal  Carrier  0  0  0  2  14.6 
* Test duration  was  6-8 h.  Spontaneous  release was <20%.  All samples were assayed  in triplicate 
and standard error was <2%. 
5  X  10 7 spleen cells from 6-10-wk-old BALB/c WEHI mice were transferred  intravenously into 
2-4-too-old BALB/c WEHI mice irradiated (600 rad) 1 d previously. At the time of the cell transfer 
all recipient mice were infected intravenously with 2  x  l0 p PFU of LCMV Armstrong.  LCMV- 
specific antibody and CTL were checked 8 d postinfection. 
§ Not tested. 
1,000-fold  lower  than  N  ~  N  mice), and  were  unable  to clear the infection.  C 
+  N  ~  N  mice made  vigorous  LCMV-specific  antibody  responses  but poor  CTL 
responses, and contained  high levels of virus in the spleen until  15 d  postinfection. 
Since CTL  activity was measured  by a  51Cr-release assay,  it could be argued  that 
LCMV-infected  cells in the spleens ofN  +  C ~  N  mice acted as "cold" competitors 
in the cytotoxicity assay, thus exerting  a  pseudosuppressive  effect. This was tested 
by mixing  spleen cells from  C  +  N  ~  N  mice with spleen cells from  N  ---* N  mice AHMED ET  AL.  527 
TABLE  III 
Spleen Cells  from LCMV Carrier Mice Can Generate Vaccinia Virus- 
specific CTL Response 
Source of spleen 
cells transferred* 
Experiment 1  Experiment 2 
Percent specific 51Cr  Percent specific 5~Cr 
release from B.10.D2  release  from B.10.D2 
(H-2  a) targets*  (H-2  d) targets* 
Vaccinia  Vaccinia 
Uninfected  infected  Uninfected  infected 
None  0  9  0  14 
0  7  0  9 
Normal  2  48  2  61 
2  52  3  69 
0  43  1  61 
0  50 
Carrier  0  52  2  46 
0  22  6  64 
O  43  2  60 
0  51 
0  28 
* 5  x  107  spleen cells from  6-10-wk-old BALB/c WEHI  mice were 
transferred intravenously into 2-4-too-old normal BALB/c WEHI mice 
irradiated (600 rad) 1 d previously. At the same time, all recipient mice 
were infected intravenously with 106  PFU  of vaccinia virus (IHD-J 
strain). 
* Mice were sacrificed 7 d postinfection and CTL activity was checked on 
vaccinia virus-infected and uninfected B.10.D2 (H-2  a) targets in a 6 h 
n~Cr release assay. Spontaneous release was 15-30%. The data shown is 
percent specific killing at an effector/target ratio of 50:1. 
in  a  1:1  ratio  during  the  51Cr-release  assay;  however,  no  inhibition  occurred 
(data not shown). Thus, the low level of killing by spleen cells from C  +  N  ~  N 
mice does represent fewer CTL. Our results show that spleen cells from carrier 
mice actively suppress the LCMV-specific CTL response of normal adult spleen 
cells.  The  suppression  is  specific  for  the  CTL  response  and  has  no  effect  on 
LCMV-specific antibody response.  The  kinetics and  magnitude of the  LCMV- 
specific antibody response  were  similar  in  N  ~  N  and  C  +  N  ~  N  mice.  The 
LCMV-specific antibody was predominantly (>80%) of the IgG class in both N 
--* N  and  C  +  N  ~  N  mice (data  not shown).  It should be noted that  N  ~  N 
mice that made both antibody and CTL responses against LCMV cleared virus 
from their spleens by day 10, whereas C +  N --* N mice that made potent LCMV- 
specific antibody responses but poor or undetectable CTL responses contained 
high levels of infectious LCMV in their spleens at day 15. 
Suppression of LCMV-specific CTL Response Is Associated  with the Establishment of 
Persistent LCMV Infection.  Groups of N  ~  N,  C  ~  N, and C  +  N  ~  N  mice 
were  examined  for  viremia  by  sampling  blood  on  days  28,  41,  68,  and  99 
postinfection and determining LCMV titers by plaque assay on Vero cell mono- 
layers. N  ~  N  mice had no detectable LCMV, whereas C ~  N and C +  N ~  N A 
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FIGURE  1.  Effect  of  carrier  spleen  cells on  the  generation  of  LCMV-specific  CTL  and 
antibody responses. The suppression of CTL response is associated with the inability to clear 
virus infection. 5 ×  107 spleen cells from the indicated source were transferred intravenously 
into 2-4-too-old normal BALB/c mice irradiated (600 rad) 1 d previously. Mice reconstituted 
with both carrier and normal spleen cells received 5 x  107 cells from each source. At the time 
of the cell transfer all recipient mice were infected intravenously with 2  x  105 PFU of wild- 
type LCMV  Armstrong.  At various times postinfection mice were checked for (.4)  LCMV- 
specific CTL, (B) LCMV-specific antibody, and (C) LCMV titer in spleen. CTL activity in the 
spleen was determined by a  6-8 h nlCr-release assay. LCMV-specific antibody was measured 
by an ELISA test using purified virus as antigen. The titer of infectious LCMV was determined 
by plaque assay on Vero cell monolayers. Each point represents the mean of at least three 
mice. The day 8 point contains >20 mice. The bars indicate the range. AHMED  ET  AL.  529 
TABLE  IV 
Irradiated Mice Reconstituted  with Mixtures of Spleen  CeUs  from Normal and Carrier Mice 
Fail to Clear the Virus Infection  and Become LCMV Carriers 
LCMV titer in serum* (log~0  LCMV titer at 99 d postinfection  (log10 
Normal  PFU/ml)  PFU/organ)0 
Source of  recipi-  ent  Days postinfection 
spleen cells  (600  Lymph 
transferred*  rad)  No.  28  41  68  99  node  (in-  Thy-  mus  Spleen  Kid-  ney  Brain 
guinal) 
Normal 
Carrier 
1  <1.3  <1.3  <1.3  <1.3  <1.6  <1.6  <1.6  <1.6  <1,6 
2  <1.3  <1.3  <1.3  <1.3  <1.6  <1.6  <1.6  <1.6  <1.6 
3  <1.3  <1.3  <1.3  <1.3  <1.6  <1.6  <1.6  <1.6  <1.6 
1  3.5  3.6  5.0  5.1  6.1  5.5  5.9  6.7  5.9 
2  3.5  3.8  5.0  5.5  4.8  5.1  5.0  6.3  5.7 
3  3.4  3.9  5.1  4.9  5.5  6.1  5.2  6.9  4.9 
Normalplus  1  3.6  3.8  4.7  4.7  5.7  6.1  5.0  6.8  5.5 
carrier  2  3.8  3.5  4.9  4.9  5.6  5.5  5.8  6.6  6.1 
3  3.9  3.8  4.5  5.0  5.2  5.0  4.9  6.4  5.6 
4  3.3  3.3  4.4  4.6  5.9  5.8  5.7  6.7  5.7 
* 5 X 107 spleen cells from 6-10-wk-old BALB/c WEHI mice were transferred intravenously  into 
2-4-mo-old normal BALB/c WEHI mice irradiated (600 rad) 1 d previously.  Mice reconstituted 
with both carrier and normal spleen cells received 5 x  107 cells from carrier mice and 5 x  107 cells 
from normal mice. At the time of the cell transfer all recipient  mice were infected  intravenously 
with 2 x  105 PFU of LCMV Armstrong. 
* Mice were eye-bled  and the virus  titer  in  the serum was determined by titration  on Vero cell 
monolayers. 
Mice were sacrificed  and the various organs harvested,  homogenized, and titrated on Vero cell 
monolayers. 
mice  contained  high  levels  of  infectious  LCMV  (Table  IV).  The  mice  were 
sacrificed 99 d  after  infection,  at which time  we found high  levels of LCMV  in 
the spleens,  lymph nodes,  thymuses,  kidneys,  and brains of all  C  ~  N  and C  + 
N  ~  N  mice tested (Table IV). Thus, these C ~  N  and C  +  N  ~  N  mice became 
long-term carriers.  Most interestingly,  C  +  N  ~  N  mice failed to clear the virus 
infection  despite  making  a  strong  LCMV-specific  antibody  response.  Taken 
together,  these  results  demonstrate  that  the  establishment  of persistent  LCMV 
infection is associated  with  the suppression  of LCMV-specific CTL  response. 
We next tested whether  the transfer of spleen  or lymph node cells containing 
LCMV-specific CTL  would  result  in  virus  clearance  and prevent  establishment 
of the carrier state.  Spleen or lymph node cells from normal adult mice infected 
8  d  previously with  LCMV  Armstrong  were  used as a  source of LCMV-specific 
CTL.  5  ×  107 day 8  spleen  or lymph node cells were mixed with 5  x  107 carrier 
spleen  cells  and  transferred  intravenously  into  irradiated  normal  mice.  At  the 
time of the cell transfer all recipient mice were infected with LCMV Armstrong. 
Mice  were sacrificed at days 3  and  7  postinfection  and  the virus titer  in various 
organs  and  sera  was  determined  by plaque  assay  on  Vero  cells  (Table  V).  As 
before (Fig.  1 and Table  IV),  mice reconstituted  with  carrier  spleen  cells alone 
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TABLE  V 
Transfer of Spleen or Lymph Node Cells Containing LCMV-specific CTL Results in Virus Clearance 
and Prevents Establishment of the Carrier State 
LCMV titer (Iogl0 PFU/organ  or ml  ~) 
Day 3 postinfection  Day 7 postinfection  Source of cells trans- 
ferred*  Axitlary  Inguinal  Axillary  Inguinal 
Spleen  lymph  lymph  Thymus  Serum  Spleen  lymph  lymph 
node  node  node  node 
Thymus  Serum 
Carrier spleen  6.2  6.0  5.4  4.9  <1.6  6.3  5.8  5.7  5.8  4.3 
6.2  6.1  6.0  4.9  <1.6  6.3  5.6  5,4  5.8  4.6 
6.0  5.2  5.0  4.6  <1,6  6.1  5.2  5.3  5.7  4.3 
Carrier spleen +  day 8  <1.6  5.4  5.0  3,3  <1.6  <1.6  <l.6  <t,6  <1.6  <1.6 
spleen I  <1.6  5,3  5.0  4.1  <1,6  <1.6  <1.6  <1.6  <1.6  <1.6 
<1.6  5,0  5.2  3.2  <1.6  <1.6  <1.6  <1,6  <1.6  <1.6 
Carrier spleen +  day 8 axil-  5.8  5.1  5.2  4.0  <1.6  <1.6  <1.6  <1,6  <1.6  <1.6 
lary  LN 0  5.7  5.3  4.5  3.9  <1.6  <1.6  <1.6  <1,6  <1.6  <1 ~6 
4.3  4.4  4,8  4.0  <1,6  <I,6  <1,6  <1.6  <i,6  <1,6 
Carrier spleen +  day 8 in-  5.3  5.2  4.4  4.0  <1.6  <1.6  <1.6  <1,6  <1.6  <1,6 
guinal LN I  5.5  5.5  5.3  4.2  <1.6  <1.6  <1.6  <1.6  <1.6  <1.6 
5.4  5.1  5.0  4.6  <1,6  <1.6  <1.6  <1.6  <1.6  <1.6 
* 5  ×  107 ceils from 6-10-wk-old BALB/c WEHI mice were transferred intravenously into 2-4-too-old  normal BALB/c WEH! mice irradiated 
(600 rad)  1 d  previously.  Mice reconstituted  with both carrier spleen cells and day 8  spleen (or day 8  LN'~cells) received  5  ×  107 cells from 
each source. At the time of the cell transfer all recipient mice were infected intravenously  with 2 ×  10  s PFU of LCMV Armstrong. 
* Mice were sacrificed and the virus titer in the various organs and serum determined by plaque assay  on Veto cell monolayers. 
I Spleen and lymph node (LN) cells from 6-10-wk-old normal  BALB/c WEHI mice infected intravenously  8  d  previously  with 2  ×  10  s PFU 
of LCMV Armstrong. 
carrier  spleen  cells  and  day  8  spleen  or  lymph  node  cells  cleared  the  virus 
infection  within  7  d.  These  mice  contained  no detectable  infectious  LCMV  in 
the serum or any of the organs tested.  It should be noted that day 8 lymph node 
cells did not reduce the virus titer in any organ at 3 d postinfection, whereas day 
8  spleen  cells  had  effectively  cleared  the  infection  from  the  spleen  by  day  3 
postinfection  although high  levels  of LCMV  were  present  in the  lymph  nodes 
and the thymus. This  may represent  preferential  homing of day 8  spleen  cells 
into the spleen of recipient mice. 
Suppression of LCMV-specific CTL Response by Carrier Spleen Cells Is Not Mediated 
by a Suppressor Cell.  Carrier spleen cells subjected to x irradiation  (3,000  rad), 
anti-theta plus complement treatment, or sonication were tested for their ability 
to suppress  LCMV-specific  CTL  responses.  As Table  VI  shows,  none of these 
treatments  abrogated  suppression,  indicating  that  inhibition  of LCMV-specific 
CTL response by carrier spleen cells does not require intact cells and is unlikely 
to  be  due  to  suppressor  cells.  As  in  the  earlier  experiments,  LCMV-specific 
antibody responses were not affected,  and CTL suppression was associated with 
an inability to clear the virus infection. 
Suppression  of LCMV-spec~c  CTL  Response  Is  Due  to  the  Presence  of Genetic 
Variants of  LCMV in Carrier Spleen Cells.  Approximately  1% of spleen cells from 
BALB/c  WEHI  carrier  mice  score  as  LCMV  infectious  centers  (IC).  In  these 
transfer experiments carrier spleen cells contained 0.28-2.4%  LCMV IC. Since 
5  ×  10 v carrier spleen cells were transferred  into each recipient,  the number of 
LCMV  IC transferred  ranged  from  1.4  ×  105  to  1.2  ×  106.  When  the carrier AHMED  ET  AL.  531 
TABLE  VI 
Suppression of LCMV-specific CTL Response by Carrier Spleen Cells Is Not Abrogated by x 
Irradiation,  Anti-theta Treatment, or Sonieation of Carrier Spleen Cells 
LCMV-specific 
CTL in spleen  j 
Percent specific  LCMV-spe- 
Source of spleen  Treatment of carrier  ~Cr release from  cific anti-  LCMV  titer 
cells transferred*  spleen cells  *  BALB CI-7 (H-2  d)  body in  in spleen~ 
targets (E/T, 50:1)  serum  ~ 
LCMV 
Unin-  Arm-  ELISA titer  Log10  PFU/ 
fected  strong  (log 2)  spleen 
infected 
Normal (N) 
Carrier (C)  None 
N + C  None 
N + C  Anti-theta + C' 
8  68  14.8  <1.6 
7  64  16.0  <1.6 
14  65  13.3  <1.6 
1  0  <4.9  4.3 
3  1  <4.9  4.5 
2  2  <4.9  5.3 
2  11  16.3  5.5 
0  8  15.8  5.3 
1  6  14.7  5.5 
0  16  15.9  5.6 
6  14  16.4  5.2 
0  13  16.0  5.1 
N + C  3,000 rad  0  0  13.7  4.1 
0  0  14.0  3.7 
N + C  Sonication  4  13  15.5  5.2 
6  15  16.4  5.3 
0  8  14.7  4.7 
* 5 X  10  7 spleen cells from 6-10-wk-old BALB/c WEHI mice were transferred intravenously into 
2-4-mo-old normal BALB/c WEHI mice irradiated (600 rad)  1 d previously, At the time of the 
cell transfer all recipient mice were infected intravenously  with 2 x  105 PFU of LCMV Armstrong. 
* 5 x  107 spleen cells from carrier mice were  treated as indicated and then mixed with  5 x  107 
spleen cells from normal mice and transferred intravenously  into irradiated recipients. 
0 LCMV-specific CTL, antibody, and virus titer were  checked  8 d  postinfection.  E/T, effector/ 
target. 
spleen cells were sonicated, titration of the sonicated lysate revealed that 4  x  10 5 
PFU of LCMV were transferred into each recipient. We have found that injection 
of up to  10 7 PFU of LCMV Armstrong induces a  CTL  response, and that the 
infection  is  cleared  within  8-10  d  (data  not  shown).  This  suggested  that,  if 
suppression  of  CTL  response  was  due  to  the  carried-over  virus,  the  LCMV 
present in  spleens of carrier  mice  may  be  a  genetic variant or  in a  form  that 
induces  suppression.  To  check  this  possibility,  LCMV  was  isolated  from  the 
spleens of 2-mo-old carrier mice infected at birth with LCMV Armstrong. Spleens 
from  three carrier mice were  pooled,  homogenized, and titrated on Vero cell 532  VIRAL  PERSISTENCE:  VIRUS  VARIANTS  AND  CTL  RESPONSE 
monolayers.  Well-isolated plaques  were picked  and  subjected to  two additional 
cycles of plaque to plaque purification and then grown up in BHK-21  cells. Four 
such triple-cloned LCMV spleen isolates, clones 1,  3,  13, and  14, were tested for 
their ability to induce  LCMV-specific CTL  and antibody responses (Table VII). 
Irradiated normal mice were reconstituted with 5  x  107 spleen cells from normal 
mice and challenged with either LCMV  Armstrong  or one of the LCMV  spleen 
isolates.  Mice  infected  with  2  ×  105  or  2  x  106  PFU  of  LCMV  Armstrong 
generated  good  CTL  and  antibody  responses  and  cleared the  virus  from  their 
spleens by day 8  postinfection. One of four mice had residual amounts (2.3  log10 
TABLE  VII 
Suppression of LCMV-specific CTL Response by Carrier Spleen Cells Is Due to the Presence of 
Genetic Variants of LCMV in Carrier Mice 
LCMV-specific CTL in 
spleen* 
Percent specific 5JCr release 
Source of  Dose  from BALB CI-7 (H-2 a) tar-  body in 
spleen cells  Challenge virus  (PFU)  gets (E/T, 50:1)  serum* 
transferred* 
LCMV  LCMV  Logi0  Unin-  Arm-  ELISA ti-  clone 13  PFU/ 
fected  strong  infected  ter (log 2)  spleen 
infected 
LCMV- 
specific  LCMV ti- 
anti-  ter in 
spleen* 
Normal  LCMV Armstrong  2 ×  l05  0  62  52  12.5  <1.6 
2 X 105  0  41  38  12.9  <1.6 
2 X 106  0  53  40  14.0  2.3 
2 x  106  2  59  47  13.6  <1.6 
Normal  LCMV clone 1  2 ×  l05  0  17  19  ll.3  3.8 
2×  105  11  18  18  14.1  4.1 
2 ×  106  0  16  24  12.7  4.3 
2 x  106  0  24  14  11.2  4.7 
Normal  LCMV clone 3 
Normal  LCMV clone 13 
2 ×  105  0  16  22  11.6  4.0 
2 ×  105  0  7  0  10.9  4.8 
2 ×  106  0  16  15  12.7  4.9 
2 ×  106  0  8  0  15.0  5.0 
2 ×  105  0  7  2  11.6  5.2 
2 ×  l05  0  6  0  12.4  5.1 
2 ×  106  0  14  18  12.8  5.0 
2 ×  106  0  19  22  11.9  5.1 
Normal  LCMV clone 14  2 x  105  0  12  19  12.3  4.4 
2 x  105  0  18  19  12.7  4.1 
2 X 10  6  0  7  7  11.8  3.9 
2 X 106  0  6  7  12.7  3.9 
* 5 ×  107 spleen cells from adult BALB/c WEHI mice were transferred intravenously  into normal 
adult BALB/c WEHI mice irradiated (600  rad)  1 d previously.  At the same time recipient mice 
were infected intravenously  with the indicated virus. LCMV clones  1, 3,  13, and 14 were isolated 
from the spleens of 2-too-old carrier mice infected at birth with LCMV Armstrong. 
* LCMV-specific CTL, antibody,  and  virus  titer were checked 8  d  postinfection.  E/T,  effector/ 
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PFU) of LCMV left in  the spleen.  In  striking  contrast,  mice infected with  the 
same doses (2 ×  10 ~ and 2 x  106 PFU) of LCMV clones isolated from spleens of 
carrier  mice  made  poor  CTL  responses  and  were  unable  to  clear  the  virus 
infection.  All  four  LCMV  spleen  isolates were present  in  high  titers  (3.8-5.2 
log10 PFU) in  the spleens of recipient  mice at 8 d  after infection.  It should be 
noted that  LCMV-specific CTL induced by Armstrong strain  or by the LCMV 
spleen  isolates  were  cross-reactive  and  killed  syngeneic  targets  infected  with 
either  clone  13  or Armstrong  with  equal  efficiency.  In  other experiments  we 
tested the reactivity of CTL generated during infection with LCMV clones 1, 3, 
and 14 on targets infected with the homologous LCMV clones and found minimal 
killing  (<20%)  in  all  instances  (data  not  shown).  Thus,  the  data in  Table  VII 
showing  limited  CTL  activity  after  infection  with  the  LCMV  spleen  isolates 
represent  fewer CTL and  not the lack of appropriate  targets.  All four LCMV 
spleen isolates induced good LCMV-specific antibody responses. The amount of 
LCMV-specific antibody made after infection with the spleen isolates was equiv- 
alent to that induced by LCMV Armstrong. Thus, infection of N ~  N mice with 
LCMV spleen  isolates from  carrier  mice resulted  in  good antibody responses, 
poor CTL  responses,  and  an  inability  to clear the  virus.  The  same pattern  of 
LCMV-specific immune responses and outcome of infection was seen in C  +  N 
N  mice.  These results suggest that  the suppression  of LCMV-specific CTL 
responses and the establishment of persistent infection by carrier  spleen cells is 
due  to  the  presence  of genetic  variants  of LCMV  in  carrier  mice.  This  was 
further tested by coinfecting N  ~  N  mice with  LCMV Armstrong and  LCMV 
clone  13, and  then  checking CTL and antibody responses and the presence of 
virus (Table VIII). LCMV clone 13 selectively suppressed the CTL response and 
had  no effect on  the antibody  response.  Moreover,  the  CTL  suppression  was 
associated with an inability to clear the virus, and all  N ~  N mice infected with 
LCMV  clone  13  or  coinfected  with  LCMV  Armstrong  and  LCMV  clone  13 
became long-term carriers.  High levels of infectious LCMV were present in the 
sera of these mice at 90 d after infection. Thus, the results presented in Tables 
VII and VIII  show that active suppression  of CTL responses by carrier  spleen 
cells and the associated persistent infection are due to genetic variants of LCMV 
in spleens of carrier mice. 
Discussion 
We  have  examined  the  interaction  between  LCMV and  the  host's  immune 
system and  defined conditions  that  lead to viral  clearance  or persistence.  Our 
study establishes the following major points:  (a) Spleen  cells from carrier  mice 
actively suppress LCMV-specific CTL responses of spleen cells from normal adult 
mice.  (b)  Suppression  is  specific  for  the  CTL  response  and  LCMV-specific 
antibody responses are not affected. (c) Suppression of CTL response is associated 
with  the establishment  of persistent  infection.  (d) Transfer  of spleen or lymph 
node cells containing LCMV-specific CTL results in virus clearance and prevents 
establishment of the carrier state. (e) Suppression of CTL response is caused by 
genetic  variants  of LCMV  in  spleens  of carrier  mice.  We  propose  that  these 
LCMV  variants  selected  during  infection  in  vivo  play  a  crucial  role  in  the 
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TABLE  VIII 
Suppression  of CTL Response and Establishment of Persistent Infection by LCMV Clone 13, a 
Genetic Variant Isolated from Spleen of Carrier Mice 
LCMV-specific  CTL in spleen  LCMV-  LCMV titer in serum (logt0 PFU/ml) 
Percent specific StCr release  specific 
Source of  from BALB CL-7 (H-2  d) tar-  antibody  Days postinfection 
spleen cells  Challenge virus  gets (E/T, 50:1)  in serum 
transferred*  LCMV 
LCMV 
Unin-  Arm-  ELISA ti- 
clone  13  8  30  45  55  90 
fected  strongin-  infected  ter (log 2) 
fected 
Normal  LCMV Armstrong  3  58  52  13.9  <1.6  <1.6  <1.6  NT*  NT 
0  52  54  14.1  <1.6  <1.6  <1.6  NT  NT 
1  52  57  13.7  <1.6  <1.6  <1.6  NT  NT 
Normal  LCMV Clone  13  |  2  6  8  12.7  4.7  5.4  4,1  4.3  5.1 
0  0  0  14.6  4.3  5.3  4.2  4.6  4.3 
0  2  3  13.3  3.9  5.1  4.7  NT  NT 
Normal  LCMV Armstrong +  LCMV  3  7  12  13.3  4.0  5,4  4,8  5,3  4.7 
clone  13  0  6  2  13.8  4.1  5.4  4.2  5.3  3.9 
1  8  7  12.9  3.8  5.1  5.0  5.3  5.1 
* 5  ×  l0  T spleen  cells  from adult  BALB/c WEHI  mice were transferred  intravenously  into  normal adult  BALB/c WEHI  mice 
irradiated (600 tad)  1 d previously.  At the same time recipient mice were infected intravenously with 2 ×  10  n PFU of the indicated 
virus.  Mice coinfected with LCMV Armstrong and LCMV clone  13 received 2 ×  l0  s PFU of each virus.  There were six mice in 
each group. Three mice from each group were sacrificed 8 d postinfection and checked for LCMV-specific CTL and antibody. The 
remaining mice in each group were eye-bled at the indicated times and the titer of infectious LCMV in the serum was determined 
by a plaque assay on Vero cell monolayers. 
* Not tested. 
J LCMV clone 13 was isolated from the spleen of 2-too-old  BALB/c WEH 1 carrier mice inoculated at birth  with triple plaque-purified 
I.CMV Armstrong. 
The  mechanism  of CTL  unresponsiveness  in carrier mice and its role in the 
persistence  of LCMV  has  been  intensively  studied  (5,  6).  Other  investigators 
(17-19)  have shown  that carrier spleen  cells actively  suppress  the induction  of 
LCMV-specific  CTL responses of normal adult mice.  Dunlop and Blanden (19) 
showed  that  suppression  is  due  to  the  high  level  of infectious  virus  in  carrier 
spleen  cells.  Our  studies  confirm  and  extend  these  earlier  observations  by 
showing  that  suppression  is  due  to  genetic  variants  of LCMV.  These  earlier 
studies  did  not  examine  the  effect  of carrier  spleen  cells  on  LCMV-specific 
antibody  responses  or on  the  outcome  of infection.  We  have  shown  that sup- 
pression by carrier spleen cells is specific for the CTL response and there is no 
inhibition  of antibody  response  against  LCMV.  Most  significantly,  this  study 
demonstrates  the important biological  consequence of this specific suppression, 
namely that this leads to viral persistence. Transfer of spleen or lymph node cells 
containing LCMV-specific CTL resulted in viral  clearance and prevented estab- 
lishment of the carrier state. Using a different protocol, Mims and Blanden (20) 
and  Zinkernagel  and  Welsh  (14)  have  shown  the  important  role  of  LCMV- 
specific  CTL  in  protecting  mice  from  acute  LCMV  infections.  Additionally, 
Byrne and Oldstone 2 found that cloned lines of LCMV-specific,  H-2-restricted 
CTL  effectively  eliminated  virus  from  spleens  of acutely  infected  mice.  Thus, 
2 Byrne,  J.  A.,  and  M.  B.  A.  Olstone.  Cloned  cytotoxic  T  lymphocytes  act  in vivo to  clear  virus 
front  mice  acutely  infected  with  lymphocytic  choriomeningitis  virus.  Manuscript  submitted  for 
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the results of the present study along with the other reports clearly establish that 
LCMV-specific CTL play a crucial role in clearing virus during acute infection 
and in preventing the establishment of persistent infection. 
The  genetic variants  of LCMV  that  suppress  CTL  responses were  isolated 
from spleens of 2-too-old carrier mice infected at birth with triple plaque-purified 
LCMV Armstrong. We have found that  10  of 10  LCMV clones derived from 
that  original  wild-type  LCMV  Armstrong induced potent  CTL  responses (R. 
Ahmed, unpublished data).  Thus,  the original  inoculum was homogeneous in 
this  respect,  and  it  is  most  likely  that  LCMV  variants  that  suppressed  CTL 
responses  emerged during the  infection in  vivo.  Other  investigators (21,  22) 
have reported the presence of LCMV variants with different biological properties 
and  plaque  phenotypes in  the  brains  and  livers  of carrier  mice.  The  unique 
aspect of our studies is the dramatic difference we have identified in  LCMV- 
specific CTL  responses generated by LCMV  variants isolated  from spleens of 
carrier mice compared with  those generated by the  wild-type LCMV  initially 
used to infect these mice. The variants suppressed CTL responses,  leading to 
the important biological consequence of virus persistence. In striking contrast, 
wild-type LCMV induced a potent CTL response and the infection was rapidly 
cleared. Our results show that immunocompetent mice can become persistently 
infected when they are challenged with the appropriate LCMV variant. N ~  N 
mice infected with clone  13  were unable  to eliminate the virus infection and 
became  long-term  carriers.  Such  mice  have  now  been  followed  for  7'/2 mo 
postinfection and  contain  high  levels of infectious virus  in  the  serum and all 
major organs tested.  Preliminary results indicate that adult immunocompetent 
BALB/c WEHI  mice infected with LCMV variants make poor CTL responses 
and are  unable  to  clear the  virus  for at  least  6  wk postinfection (R.  Ahmed, 
unpublished data).  With  our finding that  LCMV  variants can persist  in adult 
mice,  a  model  is  now  available  for  assessing  the  initiation  of virus-induced 
autoimmune disease, the formation and deposition of immune complexes, and 
the  imbalance  of differentiated  functions  with  altered  homeostasis  in  adults 
infected with virus.  These states have previously been described only with the 
LCMV  infections  initiated  in  utero  or  at  birth  (5,  6,  35).  Further,  our  data 
indicate that immunocompetent adults can be at risk for developing a persistent 
infection when exposed to the operational variant. 
The ability of several viruses, especially those with RNA genomes, to undergo 
rapid  mutation  during  both  acute  and  persistent  infections  has  been  amply 
documented (23-26). The majority of these studies have examined the evolution 
of viruses  in  tissue  culture  cells,  and  there  have  been  relatively  few  studies 
analyzing genetic variation  in  viruses during replication  in  their natural hosts 
(23, 24). Selection of antigenic variants of visna virus during persistence in sheep, 
and of equine infectious anemia (EIA) virus in horses, has been described (27, 
28).  However, the role of these antigenic variants of visna virus and EIA virus 
in persistence and pathogenesis is  unclear. The generation of LCMV  variants 
that suppress CTL responses represents an example of a biologically meaningful 
selection.  The  LCMV-specific  CTL  response  is  important  not  only  in  virus 
clearance, but also in  the immunopathologic process causing lethal acute cho- 
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responses may, therefore, benefit both the host and the virus. If so, the selection 
of LCMV variants that suppresses CTL responses could represent a remarkable 
example of virus-host evolution towards balanced pathogenicity. Other examples 
of similar symbiotic relationships include the persistence of reovirus in  L-929 
cells and myxoma virus infections in rabbits (31, 32). 
One must consider whether the markedly low level of CTL activity detectable 
in  mice infected with  the  LCMV  variants  (or  carrier  spleen  cells) represents 
dilution of CTL as a result of disseminated infection and subsequent recruitment 
of LCMV-specific  CTL  from  the  spleen  to  other  infected  organs  (33,  34). 
Although such a  dilution effect cannot be completely ruled out,  the following 
observations suggest that  low CTL activity detectable after infection with the 
LCMV variants is due to suppression of CTL responses. (a) CTL activity is low 
not only in  the spleen but also in the inguinal, mesenteric, and axillary lymph 
nodes. (b) Virus is not cleared for at least several months, suggesting that the 
immune response generated during the infection is inadequate (i.e., suppressed). 
(c) The transfer of LCMV-specific CTL results in clearance of viral infection. 
Also, the transfer of spleen cells from adult immune mice (30-60 d after infection 
with LCMV Armstrong) results in the generation of CTL responses and subse- 
quent elimination of virus (R. Ahmed, unpublished data). Thus, when LCMV- 
specific CTL activity is present, the virus infection is cleared. (d) Mice infected 
with the LCMV variants or carrier spleen cells cannot generate secondary LCMV- 
specific CTL after stimulation in vitro. Hence, no detectable memory CTL are 
present in  the spleens or lymph nodes of these mice (R.  Ahmed, unpublished 
data). All these observations strongly suggest that infection of mice with genetic 
variants of LCMV isolated from carrier mice results in suppression of LCMV- 
specific CTL responses.  In  fact,  we have preliminary data indicating that the 
LCMV  variants  can  suppress  the generation of primary LCMV-specific CTL 
responses in vitro (R. Ahmed, unpublished data).  A final point to emphasize is 
that suppression of CTL responses and the dilution effects due to disseminated 
infection are not mutually exclusive events. Both may occur simultaneously and 
contribute to an inefficient CTL response and failure to clear the infection. 
How do the LCMV variants suppress CTL responses? One possibility is that 
these variants are lymphotropic and infect LCMV-specific CTL.  LCMV is not 
an overtly cytolytic virus and it is unlikely that infection would kill  the T  cell. 
However, functional inactivation of CTL may occur due to selective inhibition 
of differentiated functions.  Oldstone  et al.  (35)  have shown  that  infection of 
growth hormone-producing cells by LCMV turns off the differentiated function 
(i.e., growth hormone production) but does not affect the vital functions (i.e., 
host macromolecular synthesis and replication). Conceivably, infection of LCMV- 
specific CTL by the LCMV variants may inhibit their differentiation into cytolytic 
effector cells capable of clearing the viral infection. Another possible mechanism 
of suppression is based upon the findings of Fink et al. (36) and Rammensee et 
al.  (37) that CTL responses can be inhibited if antigen is inappropriately pre- 
sented on  T  cells.  Thus,  infection of T  cells by the  LCMV  variants and  the 
subsequent expression of viral proteins on the membrane of these infected cells 
may deliver a  negative signal and suppress the induction of the LCMV-specific 
CTL response. A critical difference between these two possible mechanisms of AHMED  ET  AL.  537 
suppression is that the first requires infection of a specific population of T  cells, 
i.e., LCMV-specific CTL, whereas the second involves infection of any T  cell. A 
third mechanism for CTL dysfunction is the presence of LCMV, or its antigens, 
in high concentration in the environment of the responding CTL.  Lamb et al. 
(38) showed that influenza virus-specific helper T  cell clones can be rendered 
unresponsive by high  concentrations of specific antigen;  suppression  of CTL 
responses after infection with large doses of LCMV has also been reported (39, 
40).  Our  preliminary results  indicate that  LCMV  variants replicate to  higher 
levels than wild-type LCMV Armstrong in spleens of infected mice (R. Ahmed, 
unpublished data), supporting this possibility. Our speculations on the mechanism 
of CTL  suppression  consider only the direct effects on  LCMV-specific CTL. 
Equally possible is that suppression may follow some effect of LCMV variants on 
the macrophages or helper T  cells-that may be required to generate LCMV- 
specific CTL responses. The next steps are to sort out these possible mechanisms 
of CTL suppression and to characterize the structural differences between the 
variant virus that causes CTL suppression and the wild-type virus that induces 
CTL activation. 
Summary 
We  studied  the  mechanism of lymphocytic choriomeningitis virus  (LCMV) 
persistence and the suppression of cytotoxic T  lymphocyte (CTL) responses in 
BALB/c  WEHI  mice infected at  birth  with  LCMV  Armstrong strain.  Using 
adoptive  transfer  experiments  we  found  that  spleen  cells  from  persistently 
infected (carrier)  mice actively suppressed  the  expected  LCMV-specific CTL 
response of spleen cells from normal adult mice. The suppression was specific 
for the CTL response and LCMV-specific antibody responses were not affected. 
Associated with the specific CTL suppression was the establishment of persistent 
LCMV infection. The transfer of spleen or lymph node cells containing LCMV- 
specific CTL  resulted  in  virus  clearance and  prevented establishment  of the 
carrier state. The suppression of LCMV-specific CTL responses by carrier spleen 
cells is not mediated by a suppressor cell, but is due to the presence of genetic 
variants  of LCMV  in  spleens  of carrier  mice.  Such  virus  variants  selectively 
suppress  LCMV-specific CTL responses and cause persistent infections in  im- 
munocompetent mice. In striking contrast, wild-type LCMV Armstrong, from 
which these variants were generated, induces a potent CTL response in immu- 
nocompetent mice and the LCMV infection is rapidly cleared. Our results show 
that LCMV variants that emerge during infection in vivo play a crucial role in 
the suppression of virus-specific CTL responses and in the maintenance of virus 
persistence. 
We thank Rita J. Concepcion for excellent technical assistance. 
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